Controversies Related to P Acnes Resistance and Acne Therapy

Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit.

Course Objectives:

  1. Discuss the safety and efficacy of therapeutic treatments for patients with mild-to-moderate acne vulgaris
  2. Review and discuss the latest evidence-based data on available treatment options for patients with mild-to-moderate as well as severe acne
  3. Discuss available treatment guidelines and expert opinion for the management of acne vulgaris


Accreditation:

This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Jennifer Verbesey, MD

Release Date: June 2009
Expiration Date: June 30, 2010

Millennium CME Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Millennium CME Institute, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Each physician should claim only those credits that he/she actually spent in the activity.

This activity was prepared in accordance with ACCME Essentials.

© 2009 Millennium CME Institute, Inc. All rights reserved including translation into other languages. No part of this activity maybe reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Millennium CME Institute, Inc.

Faculty Disclosure:

Presenter:
James J. Leyden, MD
Emeritus Professor of Dermatology
University of Pennsylvania
Philadelphia PA

Medical Review:
Nicole Weinreb, MD

Disclaimer
The opinions expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of DUSA, any other manufacturer of pharmaceuticals, or Millennium CME Institute, Inc. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations
Millennium CME Institute, Inc., endorses the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. All faculty are required to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations and with companies who have provided the commercial support for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

The individuals listed below have declared the following arrangements and/or affiliations:

James Leyden MD:

Consultant: Allegan, Galderma, Medicis, Obagi, Skin Medica, Stiefel

The opinions expressed in this publication are those of the participating faculty and do not necessarily reflect the opinions or the recommendations of their affiliated institutions, Millennium CME Institute, Inc., or any other persons. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this publication should not be used by clinicians without evaluation of their patients’ conditions, assessment of possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with the recommendations of other authorities.
This CME-certified webinar is made possible through an educational grant from Galderma

Directions:

The participant should read the learning objectives and view the online presentation in its entirety. After reviewing the material, the participant should complete the Activity Self-assessment Test consisting of a series of multiple-choice questions.

Upon successfully completing this activity as designed and achieving a passing score of 70% or higher on the Activity Self-assessment Test, participants will receive a continuing education credit letter awarding the appropriate credit and the Activity Self-assessment Test answers four to six weeks after the receipt of the registration and evaluation materials.

CME Testing Options